Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAS-TNK for Acute Spontaneous Deep Intracerebral Hemorrhage
NCT06868511Phase 3Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenecteplase in intracerebral hemorrhage (ICH) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoints: Modified Rankin Scale score of 0-3 at 180 days and All-cause death at 30 days. Started Apr 2025; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT06868511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06868511.